Edaravone

證據等級: L5

預測適應症: 10 個

Edaravone: From Acute Cerebral Infarction to Heparin Cofactor 2 Deficiency

One-Sentence Summary

Edaravone is a free radical scavenger originally developed in Japan as a neuroprotective agent for acute cerebral infarction, and subsequently approved internationally for amyotrophic lateral sclerosis (ALS). The TxGNN model’s top prediction is Heparin Cofactor 2 Deficiency (score: 99.47%), however no clinical trials or published literature currently support this specific indication. Importantly, the model also predicts efficacy in ALS susceptibility (rank 6, score: 98.79%), supported by 5 publications — a clinically significant finding given Edaravone’s established international approval for ALS.

Quick Overview

Item	Content
Original Indication	Acute cerebral infarction; Amyotrophic lateral sclerosis (ALS)
Predicted New Indication (Rank 1)	Heparin Cofactor 2 Deficiency
TxGNN Prediction Score	99.47%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Detailed mechanism of action data is not available from the regulatory data source. However, published literature confirms that Edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one) is a potent free radical scavenger. It works by quenching hydroxyl radicals (•OH) and inhibiting both •OH-dependent and •OH-independent lipid peroxidation, thereby protecting cells — particularly neurons and vascular endothelium — from oxidative damage. This mechanism underpins its established clinical use in acute cerebral infarction and ALS.

Heparin Cofactor II (HCII) deficiency is a hereditary coagulation disorder characterised by insufficient inhibition of thrombin and elastase, caused by a defect in the HCII protein itself. The core pathology is a protein-level coagulation defect rather than an oxidative stress-driven condition. While Edaravone’s free radical scavenging activity may theoretically reduce pro-coagulant states triggered by endothelial oxidative stress, it cannot directly compensate for HCII functional loss.

The TxGNN high score (99.47%) for this indication most likely reflects indirect network connections in the knowledge graph — for instance, shared comorbidities involving vascular endothelial dysfunction and the “thrombosis ← oxidative stress” topology — rather than a causally supported therapeutic hypothesis. This prediction should be regarded as a mathematical correlation, not a clinically actionable finding at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered for Heparin Cofactor 2 Deficiency.

Literature Evidence

Currently no related literature available for Heparin Cofactor 2 Deficiency.

⚠️ Clinically Important Finding: ALS Indications (Ranks 6–7)

While the top-ranked TxGNN prediction has no supporting evidence, the model also predicts efficacy for ALS susceptibility (rank 6, score: 98.79%) and ALS type 22 (rank 7, score: 98.77%). Edaravone is already approved by the US FDA (2017) and Japan PMDA for ALS treatment, with a completed Phase 3 RCT (Japan, n=137). The ALS indication is supported by 5 publications in this dataset and carries the strongest mechanistic rationale. For Australian clinical consideration, the ALS indication is the most actionable candidate from this Evidence Pack.

ALS Literature Evidence

PMID	Year	Type	Journal	Key Findings
38474192	2024	Systematic/Narrative Review	Int J Mol Sci	Reviews Edaravone’s •OH-quenching and anti-lipid peroxidation mechanisms; confirms clinical application in ALS and expanding use across neurodegenerative diseases
32241621	2020	Pharmacology/Chemistry Review	Bioorg Med Chem	Chemical characterisation of Edaravone as a free radical scavenger; confirms regulatory approvals for both stroke and ALS; documents stable adduct formation relevant to bioactivity
37565261	2023	Animal Study	Eur J Transl Myol	Proteomic profiling of wobbler ALS mouse model; elevated GFAP confirmed as astrogliosis marker; provides insight into neuroinflammatory components of ALS pathology
36595221	2023	In vitro Mechanistic Study	FEBS Open Bio	Motor neurons susceptible to ferroptosis via GPx4-linked lipid peroxide accumulation — directly relevant to Edaravone’s anti-lipid peroxidation mechanism of action
40672281	2025	Animal Study (Preprint)	bioRxiv	TDP-43 overexpression in zebrafish motor neurons triggers MND-like phenotypes via gain-of-function mechanism; supports ROS-TDP-43 bidirectional relationship as target for Edaravone

Australia Market Information

Edaravone is currently not registered with the TGA and has no ARTG entries. No TGA-approved products are available in Australia.

For international regulatory context: Edaravone is approved by the US FDA (trade name Radicava) and Japan PMDA (trade name Radicut) for ALS treatment. Available formulations include intravenous infusion and oral suspension. Any supply in Australia would currently require either a TGA registration application or access via the Special Access Scheme (SAS Category B) or Authorised Prescriber pathway.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. As no TGA-approved product exists, clinicians should consult the FDA-approved Prescribing Information (Radicava) or Japan PMDA Radicut package insert for comprehensive safety data.

Conclusion and Next Steps

For Heparin Cofactor 2 Deficiency (Rank 1)

Decision: Hold

Rationale: The top-ranked TxGNN prediction has no supporting clinical trials or published literature, and the mechanistic link between Edaravone’s antioxidant mechanism and a primary coagulation protein deficiency is indirect at best. This is likely a knowledge-graph topology artefact rather than a clinically meaningful signal.

To justify further investigation, the following would be needed:

Preclinical studies demonstrating any direct or indirect effect of Edaravone on HCII activity or thrombin inhibition
Identification of an oxidative stress-mediated mechanism specific to HCII deficiency pathophysiology
At minimum one published case report or mechanistic study

For ALS / Motor Neuron Disease Indications (Ranks 6–7) — Recommended Priority

Decision: Proceed with Guardrails

Rationale: Edaravone is already FDA- and PMDA-approved for ALS treatment, underpinned by a completed Phase 3 RCT (Japan, n=137). The mechanistic rationale — free radical scavenging targeting oxidative stress in motor neurons, with relevance to SOD1 mutation, TDP-43 pathology, and ferroptosis pathways — is well-established. The ALS indication should be prioritised for any Australian regulatory or clinical pathway consideration arising from this Evidence Pack.

To proceed with the ALS indication in Australia, the following is needed:

Full TGA Product Information retrieval (via Special Access Scheme or import documentation) for complete local safety profiling
Review of Australian ALS patient population size, unmet clinical need, and current standard-of-care landscape
Assessment of available formulations (IV infusion and oral suspension) against Australian clinical infrastructure
Pharmacoeconomic evaluation for potential PBS listing under the Life Saving Drugs Programme or equivalent pathway
Confirmation of DDI profile in the Australian ALS population (polypharmacy context)

⚠️ This report is intended for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application. Evidence Pack version: v4 | Data cut-off: 4 April 2026.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.